Aurinia Pharmaceuticals Inc

-0.18 (-2.13%)
Other Pre-Announcement

Aurinia Reports Second Quarter 2022 Financial Results

Published: 08/04/2022 10:27 GMT
Aurinia Pharmaceuticals Inc (AUPH) - Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results.
Q2 Loss per Share $0.25.
Q2 Revenue $28.2 Million.
$391.7 Million of Cash and Investments As of June 30, 2022.
Ema Review of Lupkynis Remains on Track With Decision Expected by End of Q3 2022.
Maintains Net Revenue Guidance Range of $115-$135 Million From Sales of Lupkynis® (voclosporin) for 2022.
Net Revenue Increased to $28.2 Million for Q2 2022.
Q2 Earnings per Share View $-0.22, Revenue View $27.1 Million -- Refinitiv Ibes Data (analyst estimates).
Cash Runway Into at Least Next Few Years.